# Efficacy of Tocilizumab in Primary Sjögren's Syndrome.

> **NCT01782235** · PHASE2,PHASE3 · COMPLETED · sponsor: **University Hospital, Strasbourg, France** · enrollment: 110 (actual)

## Conditions studied

- Primary Sjögren's Syndrome (pSS)

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01782235
- **Lead sponsor:** University Hospital, Strasbourg, France
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-24
- **Primary completion:** 2018-07-16
- **Final completion:** 2018-07-16
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01782235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01782235, "Efficacy of Tocilizumab in Primary Sjögren's Syndrome.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01782235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*